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RIPK1 regulates cell death and inﬂammation through kinase-dependent and -independent
mechanisms. As a scaffold, RIPK1 inhibits caspase-8-dependent apoptosis and RIPK3/MLKL-
dependent necroptosis. As a kinase, RIPK1 paradoxically induces these cell death modalities.
The molecular switch between RIPK1 pro-survival and pro-death functions remains poorly
understood. We identify phosphorylation of RIPK1 on Ser25 by IKKs as a key mechanism
directly inhibiting RIPK1 kinase activity and preventing TNF-mediated RIPK1-dependent cell
death. Mimicking Ser25 phosphorylation (S > D mutation) protects cells and mice from the
cytotoxic effect of TNF in conditions of IKK inhibition. In line with their roles in IKK activation,
TNF-induced Ser25 phosphorylation of RIPK1 is defective in TAK1- or SHARPIN-deﬁcient cells
and restoring phosphorylation protects these cells from TNF-induced death. Importantly,
mimicking Ser25 phosphorylation compromises the in vivo cell death-dependent immune
control of Yersinia infection, a physiological model of TAK1/IKK inhibition, and rescues the
cell death-induced multi-organ inﬂammatory phenotype of the SHARPIN-deﬁcient mice.
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Receptor Interacting Protein Kinase 1 (RIPK1) has emergedas a major signaling hub downstream of several immunereceptors, where it regulates cell death and inﬂammation
through kinase-dependent and -independent mechanisms1. As a
scaffold molecule, RIPK1 facilitates activation of the MAPK and
NF-κB pathways and inhibits caspase-8-dependent apoptosis
and RIPK3/MLKL-dependent necroptosis. On the other hand,
as a kinase, RIPK1 paradoxically induces apoptosis and necrop-
tosis following its enzymatic activation. The fact that RIPK1-
deﬁcient mice die perinatally, while mice endogenously expres-
sing a catalytically inactive version of RIPK1 reach adulthood
without developing any spontaneous overt phenotype, demon-
strates the predominant pro-survival scaffolding role of RIPK1
during development2–4. Nevertheless, RIPK1 kinase-dependent
cell death has revealed its importance in the context of host-
pathogen interactions, where it can either participate in the
control of infection or favor it5–8. In addition, RIPK1 kinase-
dependent cell death has also been demonstrated to drive the
pathogenesis of various inﬂammatory diseases in mice, which
motivated the recent clinical trials for the potential therapeutic
use of RIPK1 kinase inhibitors in human9–11. Despite these
exciting advances, the precise molecular mechanism regulating
the switch between RIPK1 pro-survival and pro-death functions
has remained poorly understood.
RIPK1 is most extensively studied in the context of TNF sig-
naling. Binding of TNF to TNFR1 results in the rapid assembly
of a receptor-bound primary complex (complex I) that includes,
among others, RIPK1, TRADD, cIAP1/2, LUBAC (composed
of SHARPIN, HOIP and HOIL-1), TAB-TAK1, and the IKK
complex (composed of NEMO, IKKα, and IKKβ). A network
of polyubiquitin chains generated by cIAP1/2 and LUBAC
tightly controls the stability of complex I and the ability of
the receptor to activate the MAPK and NF-κB signalling
pathways12,13. These ubiquitin chains, conjugated to RIPK1 and
other components of complex I, generate binding sites for the
adaptor proteins TAB2/3 and NEMO, which, respectively, recruit
TAK1 and IKKα/β to the complex, and ultimately lead to gene
expression via downstream activation of the MAPK and NF-κB
pathways14,15. RIPK1 kinase-dependent cell death is not the
default response of most cells to TNF sensing. It generally
requires further inactivation of transcription-independent mole-
cular checkpoints that prevent RIPK1 from promoting, in a
kinase-dependent way, the assembly of a secondary cytosolic
complex that either triggers caspase-8-mediated apoptosis
(complex IIb) or RIPK3/MLKL-mediated necroptosis (necro-
some)16,17. The ubiquitin chains conjugated to RIPK1 by cIAP1/2
and LUBAC in complex I have been reported to repress RIPK1
cytotoxic potential, both directly as well as indirectly by pro-
moting p38/MK2-, TBK1/IKKε-, and IKKα/β−phosphorylation
of RIPK118–26. While TBK1/IKKε- and IKKα/β-phosphorylation
of RIPK1 represents a critical brake in the TNFR1 death pathway,
phosphorylation by MK2 only serves as a second layer of pro-
tection that limits the extent of cell death in killing conditions27.
The role of IKKα/β in repressing RIPK1 cytotoxicity is NF-κB-
independent, and its physiological importance is demonstrated
by the fact that inﬂammatory pathologies caused by IKKα/β
inactivation in mice can be driven by RIPK1 kinase-dependent
cell death22,28. Defects in this IKKα/β checkpoint presumably also
explain, at least in part, the in vivo inﬂammatory phenotypes
caused by RIPK1 kinase-dependent cell death in conditions
affecting proper expression/activity of IKKα/β upstream activa-
tors, such as in NEMO-deﬁcient mice29,30, SHARPIN-deﬁcient
mice3, or mice in which TAK1/IKKs are inhibited following
Yersinia infection6. How exactly IKKα/β-phosphorylation of
RIPK1 prevents RIPK1 kinase-dependent death has, however,
so far remained unanswered.
In this study, we identify IKKα/β−mediated phosphorylation
of RIPK1 on Ser25 as a physiological brake that directly inhibits
RIPK1 kinase activity and prevents TNF-mediated RIPK1 kinase-
dependent cell death. We therefore report on a precise molecular
mechanism controlling the switch between RIPK1 pro-survival
and pro-death functions and demonstrate its physiological rele-
vance in mouse models of infection and inﬂammation.
Results
IKKα/β phosphorylate RIPK1 on Ser25 in TNFR1 complex I.
We previously reported that RIPK1 is a direct substrate of
both IKKα and IKKβ, and that the simultaneous inactivation
of IKKα and IKKβ affects RIPK1 phosphorylation in TNFR1
complex I and switches the TNFR1 response from survival to
RIPK1 kinase-dependent cell death22. To better understand this
NF-κB-independent protective role of IKKα/β, we performed
mass spectrometry (LC-MS/MS) analysis of complex I isolated
from WT and Ikkα/β−/− mouse embryonic ﬁbroblasts (MEFs) in
the hope to identify residues of RIPK1 phosphorylated by these
kinases in response to TNF (Fig. 1a, b). The LC-MS/MS analysis
generated a list of proteins containing phosphorylated residues
(Supplementary Data 1). Among them, we identiﬁed Ser6 and
Ser25 of RIPK1 to be greatly hypo-phosphorylated in absence
of IKKα/β, while Ser166 and Thr169, two autophosphorylation
residues of RIPK1, were hyper-phosphorylated (Fig. 1c). Phos-
phorylation on Ser330 was, on the other hand, unaffected by
the absence of IKKα/β. Together with the fact that Ser25 was
previously identiﬁed by LC-MS/MS as a direct substrate of
IKKs in a kinase assay making use of recombinant IKKα/β
and RIPK122, these results support direct phosphorylation of
RIPK1 on Ser25, and potentially on Ser6, by IKKα/β in TNFR1
complex I. To evaluate whether the reported lethal switch in
the TNF response obtained in IKKα/β inactivated conditions
could originate from defective phosphorylation of RIPK1 on any
of these two residues, we reconstituted RIPK1-deﬁcient MEFs
with wild-type (WT) or the phospho-mimetic S > D mutated
versions of RIPK1, and stimulated the cells with TNF in presence
of IKK inhibitor (IKKi) and caspase inhibitor (zVAD) (Fig. 1d).
Remarkably, restoring Ser25 phosphorylation, but not Ser6
phosphorylation, greatly protected the cells from RIPK1 kinase-
dependent death, as demonstrated by the reconstitution of the
MEFs with the K45A kinase-dead RIPK1 mutant or by the use
of the RIPK1 kinase inhibitor Necrostatin-1s (Nec-1s) (Fig. 1d).
Serine 25 of RIPK1 is highly conserved within mammals (Sup-
plementary Fig. 1A), and we found that the phospho-mimetic
S25D mutation similarly protected human Jurkat cells from the
death trigger (Fig. 1e), indicative of a conserved regulatory
mechanism.
Occurrence of IKKα/β-mediated Ser25 phosphorylation was
further demonstrated by speciﬁc pS25 RIPK1 immunoprecipita-
tions (IP) (Supplementary Fig. 1B) in WT and IKKα/β-inacti-
vated MEFs, obtained either by pharmacological or genetic means
(Fig. 1f–g). When visualizing RIPK1 by immunoblot after pS25
RIPK1 pull-down in WT MEFs, the signal appeared as a
phosphorylation smear, which was collapsed following post-IP
λ phosphatase treatment (Fig. 1f). These results therefore indicate
multiple phosphorylation events on the same RIPK1 molecules,
including on Ser25. Since MK2-mediated phosphorylation was
excluded by performing the experiment in MK2-inhibited
conditions, it could indicate that IKKα/β simultaneously
phosphorylate RIPK1 on multiple sites. Interestingly, kinetics of
pS25 RIPK1 IP showed that phosphorylation of RIPK1 on Ser25
was a dynamic process that peaked at 10 min of TNF stimulation
(Fig. 1h). Finally, we conﬁrmed occurrence of Ser25 phosphor-
ylation of the pool of RIPK1 associated with TNFR1 complex I by
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successively immunoprecipitating complex I and then pS25
RIPK1 from complex I (Fig. 1i). The analysis of the abundance
of RIPK1 in complex I prior and after pS25 RIPK1 depletion
also indicated that most of the RIPK1 associated with complex I
is phosphorylated on Ser25 (Fig. 1j). In contrast, Ser25
phosphorylation was poorly detected in the pool of RIPK1 non-
associated to complex I, which is visualized by analyzing the
abundance of pS25 RIPK1 in the lysate prior and after complex I
depletion (Fig. 1k–l). This indicates that phosphorylation of
RIPK1 on Ser25 predominantly occurs in complex I.
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Mimicking phospho-Ser25 protects from TNF-induced cell
death. To further address the physiological relevance of IKKα/β-
mediated pS25 RIPK1, we generated a phospho-mimetic S25D
RIPK1 knockin mouse line using the CRISPR/Cas9 technology
(Supplementary Fig 2A–B). The Ripk1S25D/S25D mice were viable,
healthy and did not develop any spontaneous overt phenotype
(Supplementary Fig. 2C–D). RIPK1 expression levels were also
indistinguishable in the organs of Ripk1+/+ and Ripk1S25D/S25D
littermates (Supplementary Fig. 2E), indicating that the S25D
mutation has no impact on RIPK1 stability. TNF stimulation of
bone marrow-derived macrophages (BMDMs) or MEFs isolated
from these mice revealed no difference in the ability of the
mutated RIPK1 to activate the MAPK and NF-κB pathways
(Supplementary Fig. 3A–B). Instead, restoring pS25 RIPK1 with
the S25D mutation greatly protected BMDMs and MEFs from
TNF-induced RIPK1 kinase-dependent apoptosis and necroptosis
induced by IKK inhibition, respectively, in the absence or pre-
sence of zVAD (Fig. 2a–g). Of note, single allele mutation of
RIPK1 provided partial protection to the death trigger (Supple-
mentary Fig. 3C, D). The protection was associated with reduced
processing of caspases (Fig. 2c), phosphorylation of MLKL
(Fig. 2f), assembly of complex IIb/necrosome (Fig. 2g), and
autophosphorylation of RIPK1 on Ser166—used as a readout
for RIPK1 kinase activation (Fig. 2c–g). Importantly, the
phospho-mimetic S25D mutation did not protect the cells from
TNF-induced RIPK1-independent apoptosis obtained by
co-stimulation with the translational inhibitor cycloheximide
(CHX)31,32, thereby demonstrating the speciﬁcity of the protec-
tion to conditions inducing RIPK1 kinase-dependent cell death
(Supplementary Fig. 3E–G). We previously reported that in vivo
administration of IKKi together with sublethal doses of TNF
results in drastic hypothermia and lethality caused by RIPK1
kinase-dependent apoptosis and necroptosis22. Remarkably,
both Ripk1S25D/+ and Ripk1S25D/S25D mice showed protection
to this lethal challenge (Fig. 2h–j). Of note, these mice were
also greatly protected from a lethal dose of TNF injected in
absence of IKKi (Fig. 2k–l), a model of Systemic Inﬂammatory
Response Syndrome (SIRS) also caused by RIPK1 kinase-
dependent apoptosis and necroptosis3,9,33. Together, these
results highlight the crucial protective role of IKK-mediated
pS25 RIPK1 against TNF-induced RIPK1 kinase-dependent cell
death in vitro and in vivo.
Phospho-Ser25 regulates the immune response against Yersi-
nia. TAK1 inactivation is also known to switch the TNF response
from survival to RIPK1 kinase-dependent death22,32. Because
TAK1 is an upstream activator of IKKα/β, we then evaluated
whether the cell death induced upon TAK1 inhibition also ori-
ginates from defective pS25 RIPK1. In accordance with this idea,
we found that pharmacological inhibition of TAK1 (TAK1i)
affected TNF-induced pS25 RIPK1 (Fig. 3a), and that restoring
pS25 RIPK1 with the S25D mutation protected BMDMs and
MEFs from TNF-induced RIPK1 kinase-dependent apoptosis
when TAK1 is inhibited (Fig. 3b–d). Interestingly, we found
that mimicking pS25 RIPK1 also protected BMDMs from
death induced by LPS in presence of IKK or TAK1 inhibition
(Fig. 3e–f). The mammalian pathogenic species of the Gram-
negative Yersinia genus inject an acetyltransferase, named YopJ/
P, into target cells. YopJ/P inhibits the catalytic activity of IKKs
and TAK1 in an attempt to escape host defenses by preventing
NF-κB- and MAPK-dependent expression of pro-inﬂammatory
mediators34–38. In response to this hijacking, TLR4/TNFR1-
mediated RIPK1 kinase-dependent apoptosis of the host cell
has evolved as a backup mechanism providing cell-extrinsic
signals to promote optimal antibacterial immunity6,21,39,40. In
line with the defect of TNF-induced pS25 RIPK1 observed in
IKKs or TAK1 inhibited conditions (Figs. 1f–g, 3a), we found that
mimicking pS25 RIPK1 protected BMDMs from YopJ/P-depen-
dent apoptosis following Y. enterocolitica (expressing YopP)
and Y. pseudotuberculosis (expressing YopJ) infection (Fig. 3g–h).
Of note, the protection observed in the Ripk1S25D/S25D BMDMs
was comparable to the one obtained in cells where RIPK1 kinase
activity was inhibited pharmacologically (Nec-1s) or genetically
(Ripk1K45A/K45A) (Fig. 3g–i). Since RIPK1 kinase-dependent
apoptosis of hematopoietic cells was shown to be required for
optimal in vivo control of Y. pseudotuberculosis infection6, bone
marrow (BM) chimeras were generated by reconstituting lethally
irradiated congenic hosts with BM from either Ripk1+/+,
Ripk1S25D/S25D, or Ripk1K45A/K45A mice (Fig. 3j). Remarkably,
Ripk1S25D/S25D and Ripk1K45A/K45A chimeras had increased bac-
terial burden in the liver and spleen when compared with WT
BM chimeras, which resulted in reduced viability (Fig. 3k–m).
Together, these results indicate that inhibition of hematopoietic
Ser25 phosphorylation of RIPK1 by YopP/J activates a backup
mechanism consisting in RIPK1 kinase-dependent cell death that
is required for proper immunity to Yersinia infection.
Defective phospho-Ser25 can drive multi-organ inﬂammation.
Chronic proliferative dermatitis in mice (cpdm) is a multi-
organ inﬂammatory disorder caused by lack of SHARPIN
expression and resulting from tissue speciﬁc induction of
TNF/TNFR1-mediated RIPK1 kinase-dependent apoptosis or
necroptosis3,41–44. In light of the reported role of SHARPIN in
TNFR1-mediated IKKα/β activation44, we found that TNF-
induced pS25 RIPK1 was defective in mouse dermal ﬁbroblasts
(MDFs) isolated from SHARPIN-deﬁcient mice (Shpncpdm/cpdm)
(Fig. 4a), and that restoring Ser25 phosphorylation with the S25D
mutation completely protected these cells from TNF-induced
RIPK1 kinase-dependent apoptosis (Fig. 4b, c). More impor-
tantly, crossing the Ripk1S25D/S25D mice with the Shpncpdm/cpdm
Fig. 1 IKKα/β phosphorylate RIPK1 on Ser25 in TNFR1 complex I. a Schematic overview of the mass spectrometry (LC-MS/MS) experiment. b Small-scale
control for the LC-MS/MS experiment. Wild-type (WT) or Ikkα/β−/− MEFs were stimulated with 1 µg/ml FLAG-hTNF, TNFR1 complex I was FLAG-
immunoprecipitated and treated with USP2 to reveal difference in RIPK1 phosphorylation proﬁles. c Relative abundance between WT and Ikkα/β−/− (DKO)
MEFs of the phosphorylated residues of RIPK1 identiﬁed by LC-MS/MS. d Ripk1−/−MEFs and e RIPK1−/− Jurkat cells were reconstituted with the indicated
RIPK1 constructs, pretreated or not with Nec-1s and ZVAD-fmk for 30min and then stimulated with 1 ng/ml (d) or 20 ng/ml (e) of hTNF. Cell death was
measured in function of time by SytoxGreen positivity and is presented as mean ± SEM of independent experiments (n= 3). Statistical signiﬁcance was
determined using two-way ANOVA followed by a Sidak (d) or Dunnett (e) post-hoc test. The signiﬁcance between samples is indicated in the ﬁgures as
follows: ∗∗p < 0.01; ∗∗∗p < 0.001; nsnon-signiﬁcant. Wild-type (f–l) or Ikkα/β−/− (g) MEFs were pretreated with the indicated compounds for 30min
before stimulation with 1 µg/ml hTNF (f–h) or 1 µg/ml FLAG-hTNF (i–l) for the indicated duration. f–h pS25 RIPK1 was immunoprecipitated and treated
with USP2 and λ phosphatase (PPase) post-IP when indicated. i–j TNFR1 complex I was puriﬁed by FLAG immunoprecipitation (IP1), the complex was then
released from the beads by SDS treatment, and pS25 RIPK1 was subsequently immunoprecipitated (IP2) from the released complex I eluate. k pS25 RIPK1
was immunoprecipitated from lysates previously depleted or not of complex I by FLAG immunoprecipitation (l), and next treated with USP2 and PPase.
(b, d–l) Protein expression levels were determined by immunoblot. Immunoblots are representative of 1 (d, e, h) or 2 (b, f, g, i–l) independent experiments
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mice completely rescued the cell death-driven multi-organ
inﬂammatory phenotype of the Shpncpdm/cpdm mice (Fig. 4d–h).
For example, the phospho-mimetic S25D mutation prevented the
reported apoptosis-driven skin lesions and necroptosis-driven
splenomegaly caused by lack of SHARPIN expression, as
demonstrated by macroscopic analysis and staining of tissue
sections with H&E, TUNEL (cell death) and cleaved Caspase-3
(apoptosis) (Fig. 4d), and by the weight of the spleens (Fig. 4e).
The rescue of the phenotype is also demonstrated by the nor-
malization in the serum levels of the cell death marker LDH
(Fig. 4e), of the pro-inﬂammatory cytokine IL-6 (Fig. 4g), and of
the chemokine MCP-1 (Fig. 4h).
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Phospho-Ser25 prevents RIPK1 kinase activation in complex I.
The current model suggests that TNF-mediated RIPK1 kinase-
dependent cell death requires RIPK1 recruitment to complex I,
followed by its dissociation from TNFR1 and ﬁnally its
autophosphorylation-dependent association with FADD to initi-
ate formation of the cytosolic complex IIb/necrosome31,32,45–48.
Although low levels of RIPK1 enzymatic activity, monitored by
autophosphorylation on Ser166, have been reported in TNFR1
complex I49, it is currently unclear whether the boost in RIPK1
kinase activity associated with RIPK1 kinase-dependent cell death
occurs in complex I or only upon dissociation from complex I.
We previously showed that IKK inhibition induces cytosolic
pS166 RIPK1 and complex IIb/necrosome assembly, a set of
events that we now found to be prevented by mimicking pS25
RIPK1 (Fig. 2c–g). We also found that IKK inhibition dramati-
cally increases RIPK1 kinase activity in complex I after 10 min of
TNF sensing (Fig. 5a), which is in line with the increased
autophosphorylation detected by LC-MS/MS already after 5 min
of TNF stimulation (Fig. 1c) and that we conﬁrmed by immu-
noblot (Fig. 5b). Importantly, restoring pS25 RIPK1 with the
S25D mutation prevented the boost in pS166 RIPK1 caused by
IKK inhibition (Fig. 5c). In line with these results and the ones
presented in Figs. 3, 4, TAK1 or SHARPIN inactivation in MEFs,
BMDMs or MDFs consistently caused increased RIPK1 kinase
activity in complex I, which was also prevented by restoring pS25
RIPK1 (Fig. 5d–f). Altogether, these results therefore suggest that
conditions affecting IKK-mediated pS25 RIPK1 in complex I
induce a local boost in RIPK1 kinase activity that drives RIPK1
kinase-dependent cell death.
Phospho-Ser25 directly inhibits RIPK1 catalytic activity. Serine
25 resides in the kinase domain of RIPK1 within the β1-β2
hairpin and marks the beginning of the Glycine-rich loop in the
ATP-binding site (Fig. 6a, b), one of the most highly conserved
sequence motifs in protein kinases50. This structural motif is the
most ﬂexible part of the kinase N-lobe and is well served by this
property to seal the bound nucleotide and help positioning the γ-
phosphate of ATP for hydrolysis. The kinase domain of RIPK1
has so far only been crystalized in its inactive conformation51,52,
and structural overlays employing all known structures reveal that
Ser25 localizes at the tip of this loop and is approximately at the
same height as where the phosphate tail of ATP would be bound
in the active site (Fig. 6b). Furthermore, Ser25 is roughly halfway
between the two ordered halves of the RIPK1 activation loop and
would be expected to be adjacent to the disordered part of the
activation loop. Interestingly, Ser25 is also present in RIPK2 and
in RIPK4 (Fig. 6a) and crystal structures of active RIPK253,54 and
RIPK455 indicate that Ser25 helps to seal the nucleotide binding
site near the ribose and α-phosphate of the bound nucleotide
(Fig. 6c). Based on these structural considerations, pS25 RIPK1
would be expected to substantially alter the electrostatic proper-
ties of the Glycine-rich loop, and its interactions with adjacent
parts of the structure, including the activation loop. Thus, pS25
would be expected to impair nucleotide binding due to electro-
static repulsion or RIPK1 kinase activity due to structural per-
turbation of the activation loop. We interrogated this hypothesis
by performing kinase assays using recombinant RIPK1, which
showed that the S25D phospho-mimetic mutation greatly affected
RIPK1 kinase activity, although not as potently as the K45A
kinase-dead mutation (Fig. 6d–e). Phosphorylation on Ser25
therefore appears to function as a physiological mechanism to
directly repress RIPK1 catalytic activity during engagement of cell
surface receptors.
The anti-death role of IKKs is not limited to phospho-Ser25.
The results generated so far identiﬁed IKKα/β-mediated phos-
phorylation of RIPK1 on Ser25 as a physiological brake directly
repressing RIPK1 kinase activity. However, it remains unclear
whether the sole inhibition of this phosphorylation event sufﬁces
to activate RIPK1 in complex I and to trigger RIPK1-kinase-
dependent death upon single TNF stimulation. To address this
question, we reconstituted RIPK1-deﬁcient MEFs with WT
RIPK1 or with the S25A phospho-null mutant and stimulated the
cells with TNF. We observed that preventing pS25 RIPK1 with
the S25A mutation was sufﬁcient neither to activate RIPK1 in
TNFR1 complex I nor to trigger cell death in response to single
TNF sensing, while additional IKK inhibition similarly activated
both readouts in the two cell lines (Fig. 7a, b). The fact that the
S25A phospho-null mutation did not mimic IKK inhibition
indicates that the repressive role of IKKs on RIPK1 is not limited
to Ser25 phosphorylation, but additionally involves phosphor-
ylation of another target, which could either be another residue of
RIPK1 or another protein. It is sufﬁcient to mimic one brake on
RIPK1 (pSer25) to prevent RIPK1 activation, but all the brakes
need to be released to activate RIPK1 and to induce cell death. By
combining the S6A and S25A mutations, we excluded the
implication of IKK-mediated phosphorylation of RIPK1 on Ser6
(Fig. 7b). In addition, by challenging the S25A reconstituted cells
with TNF in presence of CHX, we also excluded genes activated
by IKK-dependent phosphorylation (Fig. 7c). Altogether, our
results support a two-signal model, whereby IKKs inhibit RIPK1
by repressing its kinase activity through Ser25 phosphorylation
and by preventing its activation through phosphorylation of a yet
to be discovered additional target (Fig. 7d–e).
Discussion
RIPK1 is a complex protein that possesses both a scaffolding pro-
survival as well as a catalytic pro-death function. Although dis-
pensable for proper development, RIPK1 kinase-dependent cell
death is beneﬁcial and promotes optimal antibacterial immunity
Fig. 2Mimicking phospho-Ser25 protects from TNF-induced cell death. a–g Ripk1+/+ and Ripk1S25D/S25D BMDMs (a, d) or MEFs (b, c, e–g) were pretreated
with the indicated compounds for 30min before stimulation with hTNF (1 ng/ml for BMDMs (a, d) and 100 pg/ml (b, e) or 20 ng/ml (c, f, g) for MEFs).
Activation of cytosolic proteins was monitored by immunoblotting (c, f, g) and cell death was measured in function of time by SytoxGreen positivity
(a, b, d, e). Cell death data are presented as mean ± SEM of three independent experiments (n= 3). BMDMs results were obtained with cells isolated from
three different mice for each genotype (n= 3) (a, d). Statistical signiﬁcance for the cell death assays was determined using two-way ANOVA followed by a
Tukey post-hoc test. h In order to demonstrate efﬁcacy of the IKKi when administered in vivo, mice were i.v. injected with IKKi (200 µg/20 g) 15min prior
to i.p. injection of mTNF (1 µg/20 g) in WT mice. Liver lysates were prepared and protein levels were determined by immunoblot. i–j Ripk1+/+, Ripk1S25D/+,
and Ripk1S25D/S25D mice were i.v. injected with IKKi (200 µg/20 g) 15 min prior to i.v. injection of mTNF (150 ng/20 g). k–l Ripk1+/+, Ripk1S25D/+, and
Ripk1S25D/S25D mice were i.v. injected with mTNF (10 µg/20 g). Cumulative survival rates (i, k) and body temperature (j, l) were determined in function of
time. The number of mice (n) used in each condition is indicated. The temperature results are represented as mean ± SEM. Statistical signiﬁcance for body
temperatures of the mice were determined using two-way ANOVA followed by a Tukey post-hoc test. Survival curves were compared using log-rank
Mantel–Cox test. Signiﬁcance between samples is indicated in the ﬁgures as follows: ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; ns non-signiﬁcant. Immunoblots
are representative of 2 (c, f, g–h) independent experiments
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in some infectious models, such as following Yersinia infection6,
but is detrimental and drives pathogenesis in various inﬂamma-
tory diseases, including in the SHARPIN-deﬁcient mice
(Shpncpdm/cpdm)3. These two examples illustrate the importance of
proper RIPK1 enzymatic regulation, but our understanding of the
precise molecular mechanism(s) regulating RIPK1 activation/
repression has so far remained limited. Indeed, the development
of speciﬁc inhibitors and the generation of kinase-dead genetic
models have been of great value to identify physio-pathological
conditions driven by RIPK1 catalytic activity, but the
physiological mechanisms that regulate the engagement of RIPK1
kinase activity remain poorly deﬁned.
Because no upstream RIPK1-activating kinase has been
reported so far, it is currently assumed that catalytic activation of
RIPK1 is caused by conformational changes induced upon
recruitment of RIPK1 to signaling platforms. Under steady state
conditions, binding of RIPK1 to chaperones, such as HSP9056, or
other proteins would maintain RIPK1 in an inactive conforma-
tion. The integration of RIPK1 to receptor signaling complexes,
such as TNFR1 complex I, would instead favor the adoption of a
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more active conformation. In such a scenario, post-translational
molecular switches within the signaling complex are therefore
required to repress RIPK1 catalytic activity in order to prevent
uncontrolled cell death induction. Conversely, the switches are
turned off in conditions of RIPK1 kinase-dependent cell death.
This could occur when RIPK1 kinase-dependent cell death is
beneﬁcial for the host, such as following Yersinia infection, or in
disease conditions caused by genetic mutations, such as the
spontaneous mutation that arose in SHARPIN in the chronic
proliferative dermatitis mice (Shpncpdm/cpdm). In accordance with
this model, we present data demonstrating that Ser25 phos-
phorylation of RIPK1 by IKKα/β in TNFR1 complex I serves as a
physiological molecular brake directly repressing RIPK1 enzy-
matic activity and, consequently, preventing RIPK1 kinase-
dependent complex IIb/necrosome assembly and apoptosis/
necroptosis induction. Within complex I, the ubiquitin chains
generated by cIAP1/2 and LUBAC (composed of HOIL-1, HOIP
and SHARPIN) act as docking stations for TAK1 recruitment and
for activation of IKKα/β by TAK1. Accordingly, TNF-mediated
pS25 RIPK1 was also affected in SHARPIN or TAK1 deﬁcient
cells, and led to catalytic activation of RIPK1 in complex I and
RIPK1 kinase-dependent cell death. Restoring RIPK1 phosphor-
ylation in these cells through expression of the S25D phospho-
mimetic RIPK1 mutant inhibited RIPK1 kinase activity at the
receptor complex and prevented TNF-induced RIPK1 kinase-
dependent cell death. In line with these results, mimicking pS25
RIPK1 also protected cells from RIPK1 kinase-dependent cell
death induced by YopJ/P, a TAK1 and IKK inhibitor that is
injected into host cells by pathogenic Yersinia species. RIPK1
kinase-dependent apoptosis of the host hematopoietic cells in
response to Yersinia infection has been reported to serve as a
backup mechanism providing cell-extrinsic signals to promote
optimal antibacterial immunity6. Accordingly, we found that
Ripk1K45A/K45A and Ripk1S25D/S25D chimeras had increased bac-
terial burden in the liver when compared with WT BM chimeras,
which resulted in reduced viability. On the other hand, crossing
the Ripk1S25D/S25D mice with the Shpncpdm/cpdm mice completely
rescued their multi-organ inﬂammatory phenotype, thereby
demonstrating the importance of Ser25 phosphorylation in two
different models in which RIPK1 kinase-dependent death is,
respectively, either beneﬁcial or detrimental for the host. Inter-
estingly, we found that the Ripk1S25D/S25D mice were also pro-
tected from the TNF-induced lethal shock caused by RIPK1
kinase-dependent cell death. This suggests that the in vivo
inﬂammatory context caused by TNF injection somehow affects
pS25 RIPK1. It was previously reported that co-sensing of TNF
with other TNF family ligands, such as TWEAK, switches the
TNF response from survival to RIPK1 kinase-dependent apop-
tosis by affecting cIAP1/2 levels57,58. Indeed, we found that the
S25D mutation also protected cells from RIPK1 kinase-dependent
apoptosis induced by TNF and TWEAK co-stimulation or by
TNF stimulation in presence of the cIAP1/2 antagonist BV6
(cIAP1/2i) (Supplementary Fig. 4A–E). In general, we observed
that the S25D mutation provided a better protection to the var-
ious RIPK1 kinase-dependent cell death triggers in MEFs and
MDFs than in BMDMs. This difference may however originate
from the in vitro setting since the S25D mutation completely
rescued the inﬂammatory phenotype of the Shpncpdm/cpdm mice,
which originates from the death of cells of various types.
Serine 25 resides in the kinase domain of RIPK1 and is located just
next to the Glycine-rich loop, a highly conserved sequence motif
within protein kinases that is reported to help coordinating the γ-
phosphate of ATP for catalysis. The analysis of all available crystal
structures of the catalytic domains of RIPK1, RIPK2, and RIPK4
predicts that Ser25 phosphorylation of RIPK1 would have an
important impact on its catalytic activity, either by impairing
nucleotide binding due to electrostatic repulsion or by structural
perturbation of the activation loop. In accordance with these pre-
dictions, we found that the S25D phospho-mimetic mutation greatly
affected RIPK1 enzymatic activity in kinase assays performed with
puriﬁed recombinant proteins. The extent of protection against
RIPK1 kinase-dependent cell death was sometimes lower with the
S25D mutation then with the K45A kinase-dead mutation or the use
of Nec-1s. This may indicate that Ser25 phosphorylation does not
fully inhibit but rather greatly represses RIPK1 activity. Alternatively,
the absence of full kinase inhibition may result from the fact that a S
>D mutation does not fully reconstitute the phosphorylated state of
the residue. Of note, the small fraction of cell death not prevented by
RIPK1 kinase inhibition in our in vitro cell death assays originates
from NF-κB inhibition, as previously reported22. The speciﬁcity of
Ser25 phosphorylation in directly repressing RIPK1 enzymatic
activity is also supported by the similarities in the phenotypes of the
Ripk1K45A/K45A and Ripk1S25D/S25D mice. Both mouse lines are viable
and fertile and only reveal their shared particularities in conditions
involving RIPK1 kinase-dependent cell death.
The fact that Ser25 of RIPK1 is only conserved within mam-
mals indicates that other mechanism(s) regulate the catalytic
activity of RIPK1 in more evolutionary distant species. Interest-
ingly, RIPK1 might not be the only family member whose cata-
lytic activity is similarly inhibited by phosphorylation. Indeed,
both RIPK2 and RIPK4 also possess a Serine residue adjacent to
their Glycine-rich loop. In the case of RIPK2, the crystal structure
of its catalytic domain bound to the non-hydrolyzable ATP
analogue AMP-PCP even indicates that the Ser25 of RIPK2
Fig. 3 Phospho-Ser25 regulates the immune response against Yersinia. aWild-type MEFs were pretreated with the indicated compounds for 30min before
stimulation with 1 µg/ml hTNF for the indicated duration. pS25 RIPK1 was then immunoprecipitated and treated with USP2 and λ phosphatase (PPase)
post-IP when indicated. b–f Ripk1+/+ and Ripk1S25D/S25D BMDMs (b, e–f) or MEFs (c, d) were pretreated with the indicated compounds for 30min before
stimulation with hTNF (10 pg/ml for BMDMs and 100 pg/ml for MEFs) (b–d) or 50 ng/ml LPS for 6 h (e) or 4 h (f). Activation of cytosolic proteins was
monitored by immunoblot (d) and cell death was measured in function of time (b–c, e–f). (g) Ripk1+/+ and Ripk1S25D/S25D BMDMs were infected with wild-
type Y. enterocolitica (Ye) or with the YopP-negative mutant Ye.ΔP in presence or absence of Nec-1s. Cell death was quantiﬁed by SytoxGreen staining 4 h
post-infection. h–i Ripk1+/+, Ripk1S25D/S25D and Ripk1K45A/K45A BMDMs were pretreated, or not, for 1 h with 5 µM IKK inhibitor BMS-345541 (IKKi), then
infected with wild-type Y. pseudotuberculosis (Yp) or the YopJ-negative mutant Yp.ΔJ. Cell death was measured by LDH 6 h post-infection (h) and cytosolic
RIPK1 activation was monitored by immunoblotting for pS166 RIPK1 (i). Cell death data are presented as mean ± SEM three independent experiments (c).
BMDMs results were obtained with cells isolated from three (n= 3) (b, e–h) different mice of each genotype. Statistical signiﬁcance for the cell death
assays was determined using two-way ANOVA followed by a Tukey (b, c, h) or Sidak (g) post-hoc test. J BM chimeras were generated by reconstituting
lethally irradiated congenic hosts with BM from either Ripk1+/+, Ripk1S25D/S25D, or Ripk1K45A/K45A mice. k–m BM chimeric mice were infected with 1–2 108
CFUs Y. pseudotuberculosis by oral gavage. Liver (k) (Ripk1+/+ n= 16, Ripk1S25D/S25D n= 13, Ripk1K45A/K45A n= 14) and spleen (l) (Ripk1+/+ n= 16,
Ripk1S25D/S25D n= 13, Ripk1K45A/K45A n= 14) bacterial burdens were measured on day 5 post-infection and survival was recorded during two weeks (m)
(Ripk1+/+ n= 6, Ripk1S25D/S25D n= 6, Ripk1K45A/K45A n= 6). Statistical signiﬁcance for the bacterial burdens was determined using a Mann–Whitney test.
Signiﬁcance between samples is indicated in the ﬁgures as follows: ∗∗p < 0.01; ∗∗∗p < 0.001. Immunoblots are representative of two (d–i) independent
experiments
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would help coordinating ATP by allowing polar contact54. The
addition of a phosphate group on this residue is therefore
expected to impair nucleotide binding due to electrostatic
repulsion.
Our study focused on TNFR1 signaling but RIPK1 also reg-
ulates signaling downstream of other immune receptors,
including CD95, DR5, TLR-3/4, and RIG-I1. Interestingly, despite
the fact that all these receptors have the potential to trigger cell
death, their default response generally consists in the activation
of the NF-κB and MAPKs pathways for the induction of
inﬂammatory mediators. It is therefore tempting to speculate
that IKKα/β-mediated phosphorylation of RIPK1 on Ser25 also
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functions as a switch to repress RIPK1 kinase activity down-
stream of these receptors. Indeed, both TLR4/TRIF and
TNFR1 signaling play an important and non-redundant role in
RIPK1 kinase-dependent apoptosis in response to Yersinia
infection39,59. RIPK1 kinase-dependent death could have evolved
as a general backup mechanism aimed at eliminating cells unable
to mount a proper immune response due to IKKα/β inactivation.
Phosphorylation of RIPK1 by IKKs on Ser25 therefore appears
to act like a guardian of IKKα/β signaling—if IKKα/β signaling
is intact, RIPK1 is in an pS25 state, and promotes survival. If
IKKα/β or TAK1 are inhibited but TNFR1 or TLR4 signaling is
engaged, RIPK1 is in a Ser25-dephospho state, leading to cell
death. This would happen physiologically during infection by
pathogens that block IKK or TAK1 activation. Further studies
will therefore be needed to evaluate the occurrence of Ser25
phosphorylation of RIPK1 by IKKα/β, or alternative kinases, in
these additional signaling pathways.
Importantly, our results also demonstrated that the repressive
role of IKKs on RIPK1 is not limited to Ser25 phosphorylation.
Indeed, the S25A phospho-null RIPK1 mutation did not mimic
the effect of IKK inhibition on RIPK1 activation and cell death
induction. This implies that IKKs maintain RIPK1 in a pro-
survival mode ﬁrst by repressing its kinase activity through Ser25
phosphorylation and secondly by preventing its activation
through phosphorylation of a yet to be discovered additional
target. This second target can either be another protein or another
residue of RIPK1. Immunoblotting of RIPK1 associated to com-
plex I reveals a phosphorylated smear that collapses in IKKα/β
inhibited conditions, suggestive of simultaneous phosphorylation
of RIPK1 by IKKα/β on multiple sites22. Our LC-MS/MS analysis
identiﬁed Ser6 as another residue of RIPK1 phosphorylated by
IKKs, but our reconstitution experiment with the S6A RIPK1
mutant excluded any implication of this residue in RIPK1 acti-
vation. Furthermore, the contribution of IKK-dependent gene
activation was also ruled out by challenging the S25A RIPK1
reconstituted cells with TNF in presence of CHX. The identiﬁ-
cation and characterization of this additional layer of RIPK1
repression by IKKα/β therefore represents an exciting challenge
for the future.
Interestingly, p38/MK2 and TBK1/IKKε were also recently
reported to phosphorylate RIPK1 to repress its activity19–21,25–
27. It is however important to mention that only IKKα/β or
TBK1/IKKε inhibition, but not p38/MK2 inhibition, sufﬁces to
switch the TNF response from survival to RIPK1 kinase-
dependent cell death. Those results not only indicate that IKKα/
β and TBK1/IKKε control a more critical brake in the TNFR1
death pathway, but also that these kinases cannot substitute for
each other in the control of RIPK1. In line with this observa-
tion, we found that IKKα/β phosphorylate RIPK1 on Ser25 in a
considerable fraction, but not in the entire pool, of RIPK1
associated to complex I. It will therefore also be interesting to
evaluate in the future if IKKα/β and TBK1/IKKε phosphorylate
identical or different fractions of RIPK1 associated with TNFR1
complex I, especially knowing that Ser25 of RIPK1 was also
identiﬁed by LC-MS/MS as an IKKε substrate in an in vitro
kinase assay26. In this study, we reveal that phosphorylation of
RIPK1 on Ser25 by IKKα/β serves as a physiological brake that
directly inhibits RIPK1 kinase activity, thereby providing
insight into the regulation of inﬂammatory cell death and a
potential target for pharmacological intervention. Under-
standing the precise functional consequences of the other
phosphorylation events and their potential to modulate the
behavior of RIPK1 in the context of Ser25 post-translational
modiﬁcations represent exciting future challenges.
Methods
Antibodies and reagents. The following antibodies were used throughout this
manuscript: anti-RIPK1 (BD Biosciences #610459, 1:2000; Cell Signaling #3493,
1:2000), anti-pSer32/Ser36 IκBα (Cell Signaling #9246, 1:2000), anti-IκBα (Santa
Cruz sc-371, 1:2000), anti-actin (MP Biomedicals #69100, 1:20000), anti-IKKα
(Cell Signaling #2682, 1:1000), anti-IKKβ (Cell Signaling #2684, 1:1000), anti-β-
tubulin-HRP (Abcam ab21058, 1:10000), anti-pThr180/Tyr182 p38 (Cell Signaling
#9211, 1:2000), anti-p38 (Cell Signaling #9212, 1:2000), anti-pThr183/Tyr185 JNK
(Invitrogen #44–682 G; 1:1000), anti-JNK (Cell Signaling #9252, 1:1000), anti-
pSer166 RIPK1 (Cell Signaling #31122, 1:1000), anti-cleaved caspase-8 (Cell Sig-
naling #9429, 1:1000), anti-caspase-8 (Abnova MAB3429, 1:1000), anti-caspase-3
(Cell Signaling #9662, 1:1000), anti-cleaved PARP (Cell Signaling #9544 S¸1:1000),
anti-pSer345 MLKL (Millipore MABC1158, 1:1000), anti-MLKL (Millipore
MABC604, 1:1000), anti-FADD (Enzo Life Sciences ADI-AAM-212-E, 1:1000),
anti-SHARPIN (Proteintech 14626–1-AP, 1:2000), anti-TRADD (Bio-Rad
AHP2533, 1:1000), anti-FLAG-HRP (Sigma-Aldrich A8592, 1:1000), and anti-
thiophosphate ester antibody (Epitomics #2686–1, 1:2000). The anti-pSer25
mRIPK1 antibody is a rabbit polyclonal custom-made antibody produced by
ThermoFisher Scientiﬁc following the 2-rabbit 90-day protocol. Brieﬂy, two rabbits
were immunized with 0.25 mg (initial injection) or 0.10 mg (booster injection at
day 14, 42, and 56) custom-made phosphorylated peptide (C-LEKTDLD(pS)
GGFGKVS-amide). Rabbit serum was collected at day 70 and was puriﬁed by
subsequent positive selection (afﬁnity towards phosphopeptide) and negative
selection steps (no afﬁnity towards non-phosphorylated peptide, C-
LEKTDLDSGGFGKVS-amide) to yield the ﬁnal puriﬁed phosphospeciﬁc antibody
(0.5 mg/ml). Phosphospeciﬁcity was further conﬁrmed by ELISA’s against the
phosphorylated and non-phosphorylated peptides. Recombinant human TNF-α
(concentration indicated in the ﬁgure legends) and its FLAG-tagged counterpart
(1 μg/ml) were purchased from the VIB Protein Service Facility (Ghent, Belgium).
LPS (50 ng/ml, Sigma–Aldrich L-2630). Fc-TWEAK was a kind gift of Prof.
Dejardin (University of Liege, Belgium) and used at 100 ng/ml. Rat recombinant
untagged USP2 was purchased from Enzo Life Sciences (BML-UW9850–0100).
Lambda protein phosphatase was obtained from New England Biolabs (P0753s).
The following compounds were used: MK2i (PF3644022: 2 μM, Tocris Bioscience),
IKKi (TPCA-1: 5 μM, Tocris Bioscience; BMS-345541: 5 μM, EMD-Millipore),
zVAD-fmk (50 μM, Bachem), CHX (concentration indicated in the ﬁgure legend,
Sigma–Aldrich), TAK1i (NP-009245: 1 μM, Analyticon Discovery GmbH; (5Z)−7-
Oxozeaenol: 1 μM, Tocris) and cIAP1/2i (BV6: 1 μM, Selleckchem). Nec-1s
(UAMC-02197: 10 μM, Laboratory of Medicinal Chemistry, University of Antwerp,
Belgium).
Fig. 4 Defective phospho-Ser25 can drive multi-organ inﬂammation. a Shpn+/+ or Shpncpdm/cpdm MDFs were pretreated with the indicated compounds
for 30min before stimulation with 1 µg/ml hTNF for the indicated duration. pS25 RIPK1 was then immunoprecipitated and treated with USP2 and λ
phosphatase (PPase) post-IP when indicated. b, c Shpncpdm/cpdm; Ripk1+/+ or Shpncpdm/cpdm; Ripk1S25D/S25D MDFs were pretreated with the indicated
inhibitors for 30min prior to 1 ng/ml hTNF stimulation. Cell death and protein activation were determined in function of time respectively by SytoxGreen
positivity (b) and immunoblot (c). Cell death data are presented as mean ± SEM of three independent experiments (n= 3). Statistical signiﬁcance for
the cell death assays was determined using two-way ANOVA followed by a Tukey post-hoc test. d Representative picture of 8-weeks-old Shpn+/+
Ripk1S25D/S25D, Shpncpdm/cpdm Ripk1+/+, and Shpncpdm/cpdm Ripk1S25D/S25D mice, and section of their skin and spleen stained for H&E, TUNEL or cleaved
caspase-3. Scale bar represents 40 µm. e Spleen weight from age-matched 8–12-weeks-old mice (Shpncpdm/cpdm Ripk1+/+ n= 19, Shpn+/+ Ripk1S25D/S25D
n= 7, Shpncpdm/cpdm Ripk1+/S25D n= 6, Shpncpdm/cpdm Ripk1S25D/S25D n= 6, Shpn+/+ Ripk1+/+ n= 6). f Lactate dehydrogenase (LDH) (Shpncpdm/cpdm Ripk1
+/+ n= 12, Shpn+/+ Ripk1S25D/S25D n= 8, Shpncpdm/cpdm Ripk1S25D/S25D n= 10, Shpn+/+ Ripk1+/+ n= 5), g IL-6 (Shpncpdm/cpdm Ripk1+/+ n= 7, Shpn+/+
Ripk1S25D/S25D n= 6, Shpncpdm/cpdm Ripk1S25D/S25D n= 6, Shpn+/+; Ripk1+/+ n= 7), and h MCP-1 (Shpncpdm/cpdm; Ripk1+/+ n= 8, Shpn+/+; Ripk1S25D/S25D
n= 7, Shpncpdm/cpdm; Ripk1S25D/S25D n= 6, Shpn+/+; Ripk1+/+ n= 7) levels were determined in the serum of 8–12-weeks-old mice. Spleen weight, LDH, IL-6,
and MCP-1 are presented as mean ± SEM from n samples from individual mice. Statistical signiﬁcance was determined by one-way ANOVA followed by
a Tukey post-hoc test. Signiﬁcance between samples is indicated in the ﬁgures as follows: ∗∗p < 0.01; ∗∗∗p < 0.001. Immunoblots are representative of
two (a, c) independent experiments
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Mice. Generation of the Ripk1S25D knockin mouse line by CRISPR/Cas9 was
outsourced to Cyagen (USA). The AGC serine-encoding codon in exon 2 of the
mouse RIPK1 locus was altered to a GAT codon encoding for glutamate. To do so,
Cas9 mRNA, gRNA (5’-gacctagacagcggaggcttcgg-3’) generated by in vitro tran-
scription and oligo donor (with targeting sequence, ﬂanked by 120 bp homologous
sequences combined on both sides) were co-injected into fertilized C57BL/6 mouse
eggs for KI mouse production. F1 heterozygous breeding pairs were obtained from
Cyagen and used for establishment of the Ripk1S25D colony. Shpncpdm mice were
kindly provided by Prof. H. Walczak and were described earlier44. Crosses between
the Shpncpdm and Ripk1S25D were validated by genotyping. All in vivo experiments
were performed with littermate mice. Primary cultures were isolated from litter-
mate mice. All experiments on mice were conducted according to institutional,
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Fig. 5 Phospho-Ser25 prevents RIPK1 kinase activation in complex I. MEFs (a–d), BMDMs (e) or MDFs (f) of the indicated genotypes were pretreated
for 30min with the indicated compounds before stimulation with 1 µg/ml FLAG-hTNF for the indicated duration. (a, c–f) TNFR1 complex I was then
FLAG-immunoprecipitated and the IPs were then treated with USP2 when indicated. b The lysates were then split in two to isolate in parallel TNFR1
complex I by FLAG immunoprecipitation and pS25 RIPK1. The IPs were respectively subsequently treated with USP2 and USP2+ PPase. Protein levels were
determined by immunoblot. Immunoblots are representative of two (a–f) independent experiments
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national and European animal regulations. Animal protocols were approved by
the ethical committee of Ghent University (EC2017–071, EC2017–079).
Cell lines. Mouse embryonic ﬁbroblasts (MEFs) and mouse dermal ﬁbroblasts
(MDFs) were cultured in Dulbecco’s modiﬁed Eagle’s medium supplemented with
10% fetal calf serum, L-glutamine (200 mM) and sodium pyruvate (400 mM) in
normoxic conditions (5% CO2). When the cells were still at the primary state, 0.1%
β-mercaptoethanol and penicillin (100 IU/ml) and streptomycin (0.1 mg/ml) was
added to the medium. Primary Ripk1+/+, Ripk1+/S25D, and Ripk1S25D/S25D MEFs
were isolated from E12.5 littermate embryos following standard protocol and
cultured under low-oxygen conditions (3% O2)60. MEFs were subsequently
immortalized by transfection of a SV40 large T-expressing construct with Jet-
PRIME (Polyplus transfection) according the manufacturer’s instructions. Wild-
type and Ikkα/β−/−MEFs were a kind gift of Prof. E. Dejardin and were previously
described22,61. Ripk1+/+ Shpn+/+, Ripk1+/+ Shpncpdm/cpdm, Ripk1S25D/S25D
Shpn+/+, and Ripk1S25D/S25D Shpncpdm/cpdm MDFs were isolated from ears of 8–10-
week-old mice. This was done by sacriﬁcing the mice and subsequently cutting of
part of the ear. This piece was then washed in 70% ethanol and the dermis was
removed from the ear with forceps. Both the dermis and the leftover part of the ear
were then plated in a six-well plate and covered with a sterile microscopy glass
cover. When the cells reached conﬂuence (after ~7 days) the cells were passaged
and transfected with SV-40 for immortalization. Bone marrow-derived macro-
phages (BMDMs) were isolated by ﬂushing the femurs and tibias of 7–10-week-old
mice with cold PBS using a 26 G needle. The cell suspension was ﬁltered
through a 70 μm cell strainer, centrifuged at 220 × g, and treated with ACK
lysis buffer to remove red blood cells. After centrifugation, the cells were resus-
pended in RPMI medium supplemented with 10% FCS, 2 mM L-Glutamate,
0.1% β-mercaptoethanol, penicillin (100 IU/ml) and streptomycin (0.1 mg/ml), and
40 ng/ml mouse M-CSF. The cells were plated in a 10 cm non-cell-culture-treated
dish and cultured for 7 days at 37 °C in a 10% CO2 incubator. The medium was
changed on day 3 and 6. On day 7, the differentiated cells were collected by
scraping in cold PBS, centrifuged at 200 × g, resuspended in medium without
growth factor, and seeded for an experiment.
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Fig. 6 Phospho-Ser25 directly inhibits RIPK1 catalytic activity. a Schematic representation of mouse RIPK1 primary structure and excerpts from structure-
based sequence alignments for murine RIPK1–4 (Uniprot sequences Q60855, P58801, Q9QZL0, Q9ERK0) focusing on the region of Ser25. b Ser25
localizes in the ﬂexible Glycine-rich loop covering the RIPK1 nucleotide binding site. Structural overlays were carried out with respect to the C-lobe of RIPK1
in complex with necrostatin-4 (pdb entry 4ITJ) and employed all available RIPK1 kinase domain structures (pdb entries 4ITH, 4ITI, 4NEU, 5HX6, 5TX5,
4M66, 4M69). The red spheres correspond to the C-alpha positions of Ser25 in the different structures. The structurally ordered parts the activation loop
are drawn in green. The intervening portion of the activation loop is disordered in all crystal structures of RIPK1 to date. c Structures of human RIPK2 in
complex with the non-hydrolyzable ATP analog AMP-PCP and RIPK4 in complex with ATP. d, e In vitro kinase assays using recombinant truncated RIPK1
mutants (AA 1–479). d Quantitative kinase activity measured by ATP consumption using the ADP-Glo kinase assay. Results are presented as a percentage
relative to the kinase activity in the wild-type protein and is the mean ± SEM of three independent kinase assays (n= 3). e Qualitative kinase activity
monitored by immunoblot and revealing RIPK1 autophosphorylation and RIPK1-mediated phosphorylation of MBP
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Immunoprecipitation. For pSer25 IPs, 7.5 × 106 cells were seeded per condition in
a 150 cm² petri dish. For TNFR1 complex I (CI) and complex II (CII) IPs, 2 × 106
cells were seeded per condition in a 60 cm² petri dish. The next day, cells were
pretreated as indicated in the ﬁgure legends and subsequently stimulated (or not)
with 1 μg/ml FLAG-hTNF (CI IP), 1 μg/ml hTNF (pS25 IP) or 20 ng/ml hTNF
(CII IP). Cells were then washed two times in ice-cold PBS and lysed in 1.2 mL
(pS25 IP) or 0.6 mL (CI and CII IPs) NP-40 lysis buffer (10% glycerol, 1% NP-40,
150 mM NaCl and 10 mM Tris-HCl pH 8 supplemented with phosphatase and
protease inhibitor cocktail tablets (Roche Diagnostics)). The cell lysates were
cleared by centrifugation at 21,000 × g for 15 min at 4 °C and the supernatants were
then incubated overnight with FLAG M2 afﬁnity gel (Sigma–Aldrich) for the CI
IPs, with protein G Sepharose 4FF (GE Healthcare)+ 25 μg anti-pSer25 RIPK1
antibody for the pS25 IPs or with protein G Sepharose 4FF (GE Healthcare)+ 3 μL
homemade polyclonal rabbit anti-mouse caspase-8 for the CII IPs. The next day,
the beads were washed three times in NP-40 lysis buffer. Beads were then resus-
pended in 60 μL 1x laemmli buffer for direct analysis. When indicated, protein
complexes were additionally deubiquitylated (by USP2 treatment) and depho-
sphorylated (by lambda protein phosphatase treatment) post-IP. To do so, beads
were resuspended after the ﬁnal wash step in 50 μL 1x DUB/λPP buffer (50 mM
Tris-HCl pH 8, 50 mM NaCl, 5 mM DTT and 1mM MnCl2). Subsequently, 1.2 μg
USP2 (Enzo Life Sciences) and 400U λ PPase were added when indicated. Enzy-
matic reactions were allowed to proceed for 30 min at 37 °C and subsequently
quenched by the addition of 12.5 μL 5x laemmli buffer. For the two successive IPs
in Fig. 1i-l, 1% SDS was used to release and dissociate the ﬁrst complex. The eluate
was then diluted 1/10 in NP-40 buffer prior to the second IP. All IPs were analyzed
by immunoblotting. Uncropped blots can be found in Supplementary Figure 5.
Mass spectrometric analysis of phospho-peptides. 5 × 106 WT or Ikkα/β−/−
MEFs were seeded in ten 150 cm² petri dishes per condition. The next day, cells
were stimulated for 5 min with 2 μg/ml FLAG-hTNF and then immunoprecipated
according to the CI IP protocol (see immunoprecipitation section). After the ﬁnal
wash step in NP-40 lysis buffer, the beads were additionally washed ﬁve times in
ice-cold PBS. Protein complexes were then eluted from the beads by addition
of 200 μL 150 μg/ml 3x FLAG-peptide (Sigma-Aldrich) in PBS, followed by
incubation for 30 min at 22 °C. The eluate was then separated from the beads by
applying the samples over Mobicol (MoBiTec) columns with a 35 μM pore size.
Proteins were then reduced, alkylated and digested using the FASP protocol. Next,
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Fig. 7 The anti-death role of IKKs is not limited to phospho-Ser25. a–c Ripk1−/− MEFs were reconstituted with the indicated Ripk1 constructs, pretreated
with the indicated compounds for 30min and stimulated with 1 µg/ml FLAG-hTNF (a) or 1 ng/ml hTNF (b, c). a TNFR1 complex I was then FLAG-
immunoprecipitated and subsequently treated with USP2. Protein levels were determined by immunoblot. b, c Cell death was then determined in function
of time by SytoxGreen positivity. Cell death data are presented as mean ± SEM three independent experiments. Immunoblots are representative of two
independent experiments (a). d, e Two-signal model of IKK-mediated repression of RIPK1, whereby IKKs inhibit RIPK1 ﬁrst by directly repressing its kinase
activity through Ser25 phosphorylation and secondly by preventing its activation through phosphorylation of a yet to be discovered additional target.
d Under normal conditions, TNF sensing induces the recruitment of RIPK1 to TNFR1 complex I, and the SHARPIN/TAK1-dependent phosphorylation of
RIPK1 by IKKs. Phosphorylation on Ser25 by IKKα/β directly represses RIPK1 enzymatic activity and consequently prevents induction of RIPK1 kinase-
dependent cell death. e In conditions affecting proper IKKα/β activation, such as following Yersinia (Ye) infection or in cells bearing the Sharpincpdm
mutation, defective phosphorylation of RIPK1 by IKKα/β lifts two brakes on RIPK1 kinase activity, resulting in increased autophosphorylation (pS166)
and RIPK1 kinase-dependent cell death. Restoring Ser25 phosphorylation (S25D mutation) in these IKKα/β-defective conditions puts one brake back
on RIPK1 enzymatic activity, which is sufﬁcient to protect the cell from death. Nevertheless, preventing Ser25 phosphorylation alone is not sufﬁcient to
induce RIPK1 kinase-dependent cell death after single TNF ligation, indicative of the existence of an additional substrate of IKKα/β functioning as a second
brake on RIPK1 activation
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phospho-peptides were enriched by using Ti4+-IMAC before LC-MS/MS analysis.
Raw mass spectrometric data were processed with MaxQuant version 1.5.3.28.
See Supplemental Information for a more detailed description of the mass spec-
trometry procedures. All raw mass spectrometry data ﬁles and MaxQuant output
ﬁles have been deposited to the ProteomeXchange Consortium (http://
proteomecentral.proteomexchange.org) via the PRIDE partner repository62 with
the dataset identiﬁer PXD009857.
Histology and analysis of serum markers. For histology, organs were ﬁxed in
4% paraformaldehyde, embedded in parafﬁn and cut at 5 μm thickness. Subse-
quently, sections were stained with hematoxylin and eosin. TUNEL assay was
performed according to manufacturer’s instructions (In situ cell death detection kit,
TMR red—Roche). For immunohistochemistry, sections were deparafﬁnized,
rehydrated and antigen retrieval was done with a citrate buffer (Vector Labora-
tories). Sections were then incubated overnight at 4 °C with a Caspase-3 primary
antibody (Cell Signaling #9661 S, 1:300) followed by a biotinylated secondary
antibody (DAKO) and ABC (Vector Laboratories). Serum LDH levels were
obtained at UZ-Gent (Belgium) using Cobas 8000 modular analyzer series (Roche
Diagnostics, Basel, Switzerland). Serum cytokines levels were measured using a
Bio-Plex Multiplex immunoassay (Bio-Rad #171304070) according to the manu-
facturer’s instructions.
TNF shock model. For the TNF shock model, 10 μg/20g mTNF (diluted in
endotoxin-free PBS pH6.8) was intravenously (i.v.) injected. For the IKKi-
sensitized shock model, DMSO stock solutions of IKKi (TPCA-1) were diluted in
endotoxin-free PBS pH6.8, in the presence of 3% Cremophor A25, and injected i.v.
in a volume of 200 μl (6% DMSO ﬁnal) at 10 mg/kg (21.6 μmol/kg) 15 min before
i.v. injection of mTNF (150 ng/20 g in 200 μl endotoxin-free PBS pH6.8). Control
mice received an equal amount (i.v.) of DMSO (6%) dissolved in DPBS (Vehicle)
15 min before the mTNF challenge. Mortality and body temperature were mon-
itored until 3 days after mTNF injection. Rectal body temperature was recorded
with an industrial electric thermometer (Comark Electronics, Norwich, UK; model
2001). Dead mice were considered to be at 25 °C.
Yersinia infections. Y. enterocolitica in vitro infections were performed with the
serotype O8 wild-type strain WA-314 and its isogenic YopP-knockout mutant Ye.
ΔP63. Prior to infection, bacterial overnight cultures grown at 27 °C were diluted
1:10 in fresh Luria-Bertani broth and grown for another 1.5 h at 37 °C to activate
the Yersinia Yop secretion machinery. Cells were infected at a ratio of 20 bacteria
per cell and gentamicin (50 μg/ml) was added 90 min after onset of infection to
prevent bacterial overgrowth. Infections with WT and isogenic YopJ-knockout
mutant Yersinia pseudotuberculosis strains (Yp and YpΔJ IP2666 strain back-
ground) were performed as previously described59. Brieﬂy, Yp strains were grown
overnight in 2x yeast-tryptone broth shaking culture overnight at 26 °C. Bacterial
cultures were diluted the next day into 2xYT containing 20 mM sodium oxalate
and 20 mM MgCl2, and grown for an additional 2 h at 26 °C followed by 1 h at
37 °C to induce Yop expression and secretion. Bacteria were harvested, washed
three3 times in pre-warmed DMEM, and used to infect BMDMs at 20 MOI.
For in vivo Yersinia pseudotuberculosis infections, BM chimeras and infections
were performed as previously published6, with the difference that 3–5 × 106 frozen
BM cells were used per mouse to reconstitute. The CFU for oral infection were
1–2 × 108 CFU/mouse by oral gavage.
Cell death assays. Cells (MEFs:10,000 per well, BMDMs: 30,000 per well) were
seeded in duplicates or triplicates the day before in a 96-well plate. The next day,
cells were pretreated with the indicated compounds for 30 min and then stimulated
with the indicated concentration of hTNF in the presence of 5μM SytoxGreen
(Invitrogen) and 20 μM Ac-DEVD-MCA (PeptaNova). SytoxGreen intensity and
caspase-3 activation was measured at intervals of 1 h using a Fluostar Omega
ﬂuorescence plate reader, with an excitation ﬁlter of 485 nm (SytoxGreen) or
360 nm (Ac-DEVD-MCA), an emission ﬁlter of 520 nm (SytoxGreen) or 460 nm
(Ac-DEVD-MCA), gains set at 1100, 20 ﬂashes per well and orbital averaging with
a diameter of 3 mm. Percentage of cell death was calculated as (induced
ﬂuorescence-background ﬂuorescence)/(max ﬂuorescence-background ﬂuores-
cence)∗100. The maximal ﬂuorescence is obtained by full permeabilization of the
cells by using Triton x-100 at a ﬁnal concentration of 0.1%. All cell death and
caspase-3 activation data are presented as mean ± SEM of n (indicated in the
Figure) independent experiments, unless stated otherwise. Cell death measured
by lactate dehydrogenase (LDH) release was performed using the Cytotox96 Assay
kit (Promega) according to manufacturer’s instruction.
Production and puriﬁcation of recombinant RIPK1. Recombinant human WT
and mutants RIPK1 (aa 1–479) were produced in Sf9 insect cells as GST-fusion
protein. hRIPK1 WT GST-fusion construct was obtained by cloning hRIPK1 WT
cDNA into the BamHI restriction site of the pAcGHLT vector (BD Biosciences),
subsequently hRIPK1 mutants were generated by quickchange mutagenesis.
Recombinant baculovirus was obtained after co-transfection of these constructs
with ProEasy linearized baculovirus (AB Vector) into Sf9 cells according to the
manufacturer’s instructions. Sf9-cell pellets were resuspended in 20 mM Tris-HCl
pH 8.0, 200 mM NaCl, 1 mM EDTA, 0.5% (v/v) Igepal CA-630, EDTA-free
Protease Inhibitor Cocktail Tablets (Roche Diagnostics). Lysates were incubated on
ice for 30 min. Insoluble proteins were removed by centrifugation at 10000 × g
for 15 min. The supernatant was applied to a Glutathione Sepharose 4FFcolumn
(GE Healthcare) pre-equilibrated with PBS pH 7.4. The GST-tagged RIP kinase was
eluted from the column with 50 mM Tris-HCl pH 8.0, 100 mM NaCl, 15 mM
reduced glutathione. Fractions containing RIPK1 were pooled and further puriﬁed
using a Superdex 75 pg column (GE Healthcare, running buffer: 20 mM Tris-HCl
pH 8.0, 100 mM NaCl). The purity of the fractions was checked by means of
SDS-PAGE, the RIPK1 fractions were pooled. 10% glycerol and 5 mM DTT were
added to the protein fraction, followed by storage at −70 °C.
Kinase assays. Quantitative in vitro kinase assays were performed by using the
ADP-Glo kinase assay kit (Promega). In brief, the different recombinant hRIPK1
were incubated at 150 nM for 4 h at room temperature in kinase assay buffer
(50 μm ATP, 25 mM HEPES pH 7.5, 25 mM NaCl, 15 mM MgCl2, 0.25 mg/ml
BSA, 0.01% CHAPS and 2 mM DTT). To convert ATP consumption into light
production, a 2:2:1 (kinase assay reaction:ADP-Glo reagent:kinase detection
reagent) ratio of the kit’s components was used. Luminescence was measured
during 1 s reads with the GloMax 96 microplate luminometer (Promega). For the
kinase assays detected by immunoblot, the different recombinant hRIPK1 were
incubated with myelin basic protein (Sigma, Cat. No M1891) in kinase assay buffer
(166 μm ATPɤS (Sigma; Cat. No A1388), 20 mM HEPES pH 7.5, 10 mM MgCl2,
and 2 mM DTT). Subsequently, proteins were alkylated with p-nitrobenzyl
mesylate (PNBM) (Abcam ab138910) for 90 min at room temperature and ana-
lyzed by immunoblotting.
Reconstitution of RIPK1-deﬁcient cells. The sequences encoding WT RIPK1
and the mutated versions of RIPK1 were cloned into pENTR3C using the cloneEZ
PCR cloning kit (GenScript). These sequences were then recombined into the
pLenti6-V5-blasticidin destination vector (for the phospho-mimetic mutants) or
the pSIN-3xHA-TRE-GW (for the phospho-null mutants) using the LR gateway
recombination system (Invitrogen). Lentiviral reconstitution of MEFs and Jurkats
was done by standard protocol. Brieﬂy, HEK293T cells were transfected using
calcium phosphate with the plasmids containing the different versions of RIPK1 in
combination with the lentiviral packaging vectors pMD2-VSVG and pCMV-
ΔR8.91. The medium was changed after 6 h, and collected 48 h post-transfection.
The virus-containing supernatant was then used to infect MEFs or Jurkats. Forty-
eight hours after infection, plasmid-containing cells were selected (10 μg/ml
blasticidin for pLenti6 containing cells and 2 μg/ml puromycin for pSIN containing
cells).
Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All raw mass spectrometry data ﬁles and MaxQuant output ﬁles have been deposited to
the ProteomeXchange Consortium (http://proteomecentral.proteomexchange.org) via
the PRIDE partner repository with the dataset identiﬁer PXD009857. Source data for all
graphs can be found in the source data graphs ﬁle. Uncropped blots can be found in
Supplementary Figure 5.
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